ACXP.US Acurx Pharmaceuticals LLC

Healthcare Biotechnology USA Stocks
0.9850 USD
Close of Nov 13, 2026
0.9457 7.54
Market cap
USD 5.97M
P/E
-
P/B
0.69x
ROE
-96.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ACXP.US undervalued?

Graham number

The Graham number of Acurx Pharmaceuticals LLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Acurx Pharmaceuticals LLC fundamental analysis

No fundamental analysis for Acurx Pharmaceuticals LLC yet.

Acurx Pharmaceuticals LLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including met…

Full company profile